Increased proton pump inhibitor and NSAID exposure in irritable bowel syndrome: results from a case-control study

BMC Gastroenterology

Volumn 12, Issue , 2012, Pages

  Keszthelyi, Daniel ^a,b   Dackus, Gwen H ^b   Masclee, Gwen M ^b   Kruimel, Joanna W ^b   Masclee, Ad A M ^b  

^a TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Intestinal permeability; Irritable bowel syndrome; NSAIDs; Proton pump inhibitors; Small intestinal bacterial overgrowth

Indexed keywords

ACECLOFENAC; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESOMEPRAZOLE; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DRUG EXPOSURE; DYSPEPSIA; FEMALE; GASTROINTESTINAL REFLUX; HUMAN; INFORMATION RETRIEVAL; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; POPULATION RESEARCH; PRESCRIPTION; RANDOM SAMPLE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COMORBIDITY; DYSPEPSIA; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; INCIDENCE; IRRITABLE BOWEL SYNDROME; MALE; MENTAL DISORDERS; MIDDLE AGED; PREVALENCE; PROTON PUMP INHIBITORS; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 84865662990     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-12-121     Document Type: Article

References (31)

1. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002, 123(6):2108-2131. 10.1053/gast.2002.37095, 12454866.
2. Akehurst RL, Brazier JE, Mathers N, O'Keefe C, Kaltenthaler E, Morgan A, Platts M, Walters SJ. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 2002, 20(7):455-462. 10.2165/00019053-200220070-00003, 12093301.
3. Kerckhoffs AP, Akkermans LM, de Smet MB, Besselink MG, Hietbrink F, Bartelink IH, Busschers WB, Samsom M, Renooij W. Intestinal permeability in irritable bowel syndrome patients: effects of NSAIDs. Dig Dis Sci 2010, 55(3):716-723. 10.1007/s10620-009-0765-9, 19255843.
4. Spiegel BM, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: unifying hypothesis or a spurious consequence of proton pump inhibitors?. Am J Gastroenterol 2008, 103(12):2972-2976. 10.1111/j.1572-0241.2008.01992.x, 2949084, 19086951.
5. Stichting Farmaceutische Kerngetallen (SKF) Facts and figures 2009 2010, Available from: http://www.sfk.nl/pdf-documenten/data-en-feiten/data-en-feiten-2009, accessed 15 August, Stichting Farmaceutische Kerngetallen (SKF).
6. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ 2008, 336(7634):2-3. 10.1136/bmj.39406.449456.BE, 2174763, 18174564.
7. van Boxel OS, Hagenaars MP, Smout AJ, Siersema PD. Socio-demographic factors influence chronic proton pump inhibitor use by a large population in the Netherlands. Aliment Pharmacol Ther 2009, 29(5):571-579. 10.1111/j.1365-2036.2008.03900.x, 19035978.
8. Goettsch WG, van den Boom G, Breekveldt-Postma NS, Smout AJ, Herings RM. Treatment patterns and health care costs of mebeverine-treated IBS patients: a case-control study. Pharmacoepidemiol Drug Saf 2004, 13(11):803-810. 10.1002/pds.997, 15386693.
9. Keszthelyi D, Jansen SV, Schouten GA, de Kort S, Scholtes B, Engels LG, Masclee AA. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Aliment Pharmacol Ther 2010, 32(9):1124-1128. 10.1111/j.1365-2036.2010.04453.x, 21039674.
10. Limsui D, Pardi DS, Camilleri M, Loftus EV, Kammer PP, Tremaine WJ, Sandborn WJ. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis 2007, 13(2):175-181. 10.1002/ibd.20059, 17206699.
11. Burgel N, Bojarski C, Mankertz J, Zeitz M, Fromm M, Schulzke JD. Mechanisms of diarrhea in collagenous colitis. Gastroenterology 2002, 123(2):433-443. 10.1053/gast.2002.34784, 12145796.
12. Mullin JM, Valenzano MC, Whitby M, Lurie D, Schmidt JD, Jain V, Tully O, Kearney K, Lazowick D, Mercogliano G, et al. Esomeprazole induces upper gastrointestinal tract transmucosal permeability increase. Aliment Pharmacol Ther 2008, 28(11-12):1317-1325.
13. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010, 8(6):504-508. 10.1016/j.cgh.2009.12.022, 20060064.
14. Ulluwishewa D, Anderson RC, McNabb WC, Moughan PJ, Wells JM, Roy NC. Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr 2011, 141(5):769-776. 10.3945/jn.110.135657, 21430248.
15. Talley NJ, Dennis EH, Schettler-Duncan VA, Lacy BE, Olden KW, Crowell MD. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol 2003, 98(11):2454-2459. 10.1111/j.1572-0241.2003.07699.x, 14638348.
16. Ford AC, Marwaha A, Lim A, Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol 2010, 8(5):401-409. 10.1016/j.cgh.2009.07.020, 19631762.
17. Locke GR, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ. Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities. Am J Gastroenterol 2000, 95(1):157-165. 10.1111/j.1572-0241.2000.01678.x, 10638576.
18. Talley NJ, Zinsmeister AR, Melton LJ. Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization. Am J Epidemiol 1995, 142(1):76-83.
19. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995, 108(5):1566-1581. 10.1016/0016-5085(95)90708-4, 7729650.
20. Kalantar JS, Locke GR, Talley NJ, Zinsmeister AR, Fett SL, Melton LJ. Is irritable bowel syndrome more likely to be persistent in those with relatives who suffer from gastrointestinal symptoms? A population-based study at three time points. Aliment Pharmacol Ther 2003, 17(11):1389-1397. 10.1046/j.1365-2036.2003.01591.x, 12786633.
21. Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993, 104(6):1832-1847.
22. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005, 128(5):1172-1178. 10.1053/j.gastro.2005.03.020, 15887101.
23. Fujimori S, Gudis K, Takahashi Y, Seo T, Yamada Y, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, et al. Distribution of small intestinal mucosal injuries as a result of NSAID administration. Eur J Clin Invest 2010, 40(6):504-510. 10.1111/j.1365-2362.2010.02290.x, 20412292.
24. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011, 141(4):1314-1322. 1322 e1311-1315, 10.1053/j.gastro.2011.06.075, 21745447.
25. Lewis SJ, Franco S, Young G, O'Keefe SJ. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther 1996, 10(4):557-561. 10.1046/j.1365-2036.1996.d01-506.x, 8853759.
26. Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006, 23(1):3-10. 10.1111/j.1365-2036.2006.02707.x, 16483265.
27. Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K, Duroux P, Nicolet M, Pignatelli B, Blum AL, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996, 39(1):54-59. 10.1136/gut.39.1.54, 1383231, 8881809.
28. Fried M, Siegrist H, Frei R, Froehlich F, Duroux P, Thorens J, Blum A, Bille J, Gonvers JJ, Gyr K. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 1994, 35(1):23-26. 10.1136/gut.35.1.23, 1374626, 8307444.
29. Spiegel BM. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective. Clin Gastroenterol Hepatol 2011, 9(6):461-469. quiz e459, 10.1016/j.cgh.2011.02.030, 21397724.
30. Choung RS, Ruff KC, Malhotra A, Herrick L, Locke GR, Harmsen WS, Zinsmeister AR, Talley NJ, Saito YA. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. Aliment Pharmacol Ther 2011, 33(9):1059-1067. 10.1111/j.1365-2036.2011.04625.x, 21395630.
31. Keszthelyi D, Masclee AA. Effects of proton pump inhibitor therapy in the distal gut: putting the pieces together. Dig Dis Sci Epub 17 Aug 2012.